GlaxoSmithKline Historical Financial Ratios

GSK Stock  USD 40.86  0.38  0.92%   
GlaxoSmithKline PLC is recently reporting on over 123 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 9.29 or Days Sales Outstanding of 95.02 will help investors to properly organize and evaluate GlaxoSmithKline PLC ADR financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Financial Ratios Analysis

GlaxoSmithKline PLC ADRFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate GlaxoSmithKline PLC investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on GlaxoSmithKline financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across GlaxoSmithKline PLC history.

GlaxoSmithKline PLC Financial Ratios Chart

GlaxoSmithKline PLC ADR financial ratios usually calculated using numerical values taken directly from GlaxoSmithKline PLC financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about GlaxoSmithKline PLC. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
At this time, GlaxoSmithKline PLC's PB Ratio is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 1.06 this year, although Book Value Per Share will most likely fall to 2.26.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity

Price To Sales Ratio

Price to Sales Ratio is figured by comparing GlaxoSmithKline PLC ADR stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on GlaxoSmithKline PLC sales, a figure that is much harder to manipulate than other GlaxoSmithKline PLC ADR multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is GlaxoSmithKline PLC ADR dividend as a percentage of GlaxoSmithKline PLC stock price. GlaxoSmithKline PLC ADR dividend yield is a measure of GlaxoSmithKline PLC stock productivity, which can be interpreted as interest rate earned on an GlaxoSmithKline PLC investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.
Most ratios from GlaxoSmithKline PLC's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's PB Ratio is quite stable compared to the past year. Free Cash Flow Per Share is expected to rise to 1.06 this year, although Book Value Per Share will most likely fall to 2.26.
 2021 2022 2023 2024 (projected)
Dividend Yield0.03820.02950.0190.0181
Price To Sales Ratio3.074.03.893.33

GlaxoSmithKline PLC fundamentals Correlations

-0.80.310.340.39-0.380.3-0.440.090.310.92-0.33-0.140.14-0.26-0.18-0.030.09-0.620.44-0.19-0.320.2-0.19-0.03-0.21
-0.8-0.26-0.74-0.390.51-0.250.610.29-0.26-0.590.48-0.20.10.36-0.08-0.460.320.75-0.68-0.290.50.13-0.280.360.44
0.31-0.260.160.57-0.291.0-0.28-0.171.00.28-0.220.160.020.22-0.010.17-0.040.030.280.09-0.24-0.070.07-0.52-0.24
0.34-0.740.160.01-0.630.15-0.68-0.40.160.06-0.630.43-0.43-0.40.410.79-0.74-0.530.780.64-0.26-0.560.65-0.52-0.32
0.39-0.390.570.01-0.110.57-0.15-0.040.570.42-0.050.170.330.41-0.27-0.090.26-0.10.06-0.12-0.690.21-0.18-0.21-0.6
-0.380.51-0.29-0.63-0.11-0.280.970.4-0.29-0.230.99-0.570.43-0.01-0.42-0.610.640.32-0.89-0.560.290.78-0.540.530.43
0.3-0.251.00.150.57-0.28-0.27-0.171.00.28-0.210.160.020.23-0.010.16-0.040.030.270.08-0.24-0.070.06-0.52-0.24
-0.440.61-0.28-0.68-0.150.97-0.270.45-0.28-0.250.98-0.60.430.03-0.41-0.630.60.4-0.91-0.560.410.71-0.540.550.53
0.090.29-0.17-0.4-0.040.4-0.170.45-0.170.150.42-0.290.460.23-0.52-0.620.660.25-0.34-0.730.120.53-0.720.390.21
0.31-0.261.00.160.57-0.291.0-0.28-0.170.28-0.220.160.020.22-0.010.17-0.040.030.280.09-0.24-0.070.07-0.52-0.24
0.92-0.590.280.060.42-0.230.28-0.250.150.28-0.17-0.340.12-0.2-0.13-0.220.22-0.530.16-0.3-0.270.32-0.30.13-0.11
-0.330.48-0.22-0.63-0.050.99-0.210.980.42-0.22-0.17-0.590.450.0-0.43-0.60.630.32-0.88-0.550.290.78-0.530.50.44
-0.14-0.20.160.430.17-0.570.16-0.6-0.290.16-0.34-0.59-0.160.570.180.56-0.40.230.660.54-0.57-0.680.48-0.59-0.73
0.140.10.02-0.430.330.430.020.430.460.020.120.45-0.160.35-0.98-0.690.720.17-0.29-0.71-0.080.65-0.730.43-0.02
-0.260.360.22-0.40.41-0.010.230.030.230.22-0.20.00.570.35-0.3-0.250.360.66-0.04-0.18-0.46-0.07-0.25-0.1-0.5
-0.18-0.08-0.010.41-0.27-0.42-0.01-0.41-0.52-0.01-0.13-0.430.18-0.98-0.30.71-0.76-0.140.250.770.04-0.670.79-0.45-0.02
-0.03-0.460.170.79-0.09-0.610.16-0.63-0.620.17-0.22-0.60.56-0.69-0.250.71-0.87-0.30.680.91-0.21-0.760.91-0.81-0.33
0.090.32-0.04-0.740.260.64-0.040.60.66-0.040.220.63-0.40.720.36-0.76-0.870.28-0.6-0.92-0.030.87-0.940.50.11
-0.620.750.03-0.53-0.10.320.030.40.250.03-0.530.320.230.170.66-0.14-0.30.28-0.42-0.170.20.02-0.20.080.13
0.44-0.680.280.780.06-0.890.27-0.91-0.340.280.16-0.880.66-0.29-0.040.250.68-0.6-0.420.54-0.38-0.690.53-0.59-0.5
-0.19-0.290.090.64-0.12-0.560.08-0.56-0.730.09-0.3-0.550.54-0.71-0.180.770.91-0.92-0.170.54-0.18-0.831.0-0.6-0.31
-0.320.5-0.24-0.26-0.690.29-0.240.410.12-0.24-0.270.29-0.57-0.08-0.460.04-0.21-0.030.2-0.38-0.180.1-0.110.320.97
0.20.13-0.07-0.560.210.78-0.070.710.53-0.070.320.78-0.680.65-0.07-0.67-0.760.870.02-0.69-0.830.1-0.820.540.29
-0.19-0.280.070.65-0.18-0.540.06-0.54-0.720.07-0.3-0.530.48-0.73-0.250.790.91-0.94-0.20.531.0-0.11-0.82-0.58-0.24
-0.030.36-0.52-0.52-0.210.53-0.520.550.39-0.520.130.5-0.590.43-0.1-0.45-0.810.50.08-0.59-0.60.320.54-0.580.42
-0.210.44-0.24-0.32-0.60.43-0.240.530.21-0.24-0.110.44-0.73-0.02-0.5-0.02-0.330.110.13-0.5-0.310.970.29-0.240.42
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamentals Accounts

201920202021202220232024 (projected)
Price To Sales Ratio4.153.143.074.03.893.33
Dividend Yield0.02820.03710.03820.02950.0190.0181
Ptb Ratio11.77.356.9511.078.859.29
Book Value Per Share3.033.664.72.633.292.26
Free Cash Flow Yield0.04180.05790.0480.04380.03390.039
Operating Cash Flow Per Share2.032.122.481.841.571.58
Stock Based Compensation To Revenue0.01170.01080.01120.01180.01010.00848
Pb Ratio11.77.356.9511.078.859.29
Ev To Sales4.923.763.654.594.392.69
Free Cash Flow Per Share1.481.561.571.280.991.06
Net Income Per Share0.781.841.171.441.371.22
Days Of Inventory On Hand182.98186.99181.92196.6221.11153.41
Payables Turnover0.790.740.660.592.442.05
Capex To Revenue(0.0641)(0.0657)(0.0859)(0.077)(0.0773)(0.0812)
Cash Per Share1.211.61.351.961.281.5
Pocfratio17.4812.713.1615.8518.625.66
Interest Coverage7.638.737.917.329.028.57
Payout Ratio1.080.850.690.910.70.82
Pfcf Ratio23.9417.2820.8422.8129.4947.48
Days Payables Outstanding459.64493.98552.2621.31149.48298.06
Income Quality1.521.321.561.51.290.97
Roe(22.53)0.830.390.290.460.42
Ev To Operating Cash Flow20.715.1715.6618.1820.9828.11
Pe Ratio30.1818.6423.8623.8523.9614.42
Return On Tangible Assets0.10.120.140.110.130.21
Ev To Free Cash Flow28.3420.6524.826.1633.2652.2
Earnings Yield0.06150.03310.05360.04190.04170.0812
Intangibles To Total Assets0.520.50.510.360.370.22
Net Debt To E B I T D A2.552.462.261.961.620.85
Current Ratio0.60.750.810.910.791.51
Tangible Book Value Per Share(5.85)(4.93)(6.02)(2.8)(2.17)(2.06)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
2.97
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.